<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124469">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482169</url>
  </required_header>
  <id_info>
    <org_study_id>10012012</org_study_id>
    <nct_id>NCT01482169</nct_id>
  </id_info>
  <brief_title>Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)</brief_title>
  <official_title>Efficacy of Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve Measurements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ochsner Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that intravenous regadenoson is equivalent to
      intravenous Adenoscan® for the physiological assessment of intermediate coronary lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective open label, single center pilot trial that will evaluate regadenoson
      compared to Adenoscan® to be given IV in the assessment of Fractional Flow Reserve. Forty
      eight subjects will be enrolled and get Adenoscan® administered via IV followed by
      Regadenoson IV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing measurement of Fractional Flow Reserve (FFR)</measure>
    <time_frame>DAY 1</time_frame>
    <description>For the first measurement of FFR, the subject will receive Adenoscan® by IV infusion. Then the FFR measurements will be taken. When vital signs have returned to normal, after two minutes the line will be flushed with saline. The subject will then receive Regadenoson by IV infusion and repeat FFR measurements will be recorded. To assist in the vital signs returning to normal, the subject will be administered aminophylline.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Adenoscan + Regadenoson</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have the FFR Measurement with IV Adenoscan® then with Regadenoson</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FFR Measurement with IV Adenoscan® then with Regadenoson</intervention_name>
    <description>Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.</description>
    <arm_group_label>Adenoscan + Regadenoson</arm_group_label>
    <other_name>Adenoscan® vs Regadenoson</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing elective left heart catheterization

          -  Age ≥ 18 years (female not of child bearing potential)

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Contraindications to administration of either Adenoscan® or Regadenoson

          -  High degree AV block, sick sinus syndrome without a functioning pacemaker

          -  Symptomatic bradycardia

          -  Recent STEMI (&lt; 5 days)

          -  Recent NSTEMI (&lt;5 days) if the peak CK is &gt; 1000 IU

          -  Dipyridamole use within 24 hours

          -  Adenoscan® is contraindicated (hypersensitivity to Adenoscan®, Regadenoson, or
             aminophylline

          -  Known severe bronchoconstrictive lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bober, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ochsner Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 28, 2016</lastchanged_date>
  <firstreceived_date>November 15, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ochsner Health System</investigator_affiliation>
    <investigator_full_name>Robert Bober, M.D.</investigator_full_name>
    <investigator_title>Director of Nuclear Cardiology</investigator_title>
  </responsible_party>
  <keyword>Left heart catheterization</keyword>
  <keyword>Fractional flow reserve</keyword>
  <keyword>Adenoscan®</keyword>
  <keyword>Regadenoson</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Regadenoson</mesh_term>
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
